Pay in 4 interest-free payments of $6.08 Learn more
Ships within 48 hours · Estimated delivery Oct 7 - Oct 12
It can also result in confusion and personality changes
Lancet 379 , 22432251 (2012)
The Legal Arguments Plaintiffs Claim: Manufacturers (Novo Nordisk, Eli Lilly) knew or should have known about risks of gastroparesis and NAION Warning labels failed to adequately disclose these serious side effects Drugs were aggressively marketed as safe and effective weight loss solutions without proper risk disclosure Patients would not have taken the medications had they known the true risks Defendants Respond: Claims are unfounded (Novo Nordisk statement) Will defend vigorously against lawsuits Motion to dismiss expected January 24, 2025 Argue that labels were adequate and that many conditions may be pre-existing or related to diabetes itself Whos Most at Risk
What "not FDA-approved" actually means for compounded medications When a compounded medication is described as "not FDA-approved," that means the FDA hasn't reviewed that specific compounded formulation for safety, effectiveness, or manufacturing quality before dispensing
US$ 23.65
US$ 24.29
US$ 22.38
US$ 29.61
US$ 29.96
US$ 22.09
US$ 26.79
US$ 27.34
US$ 22.26
US$ 27.25
US$ 28.09
US$ 22.41
